SAB Biotherapeutics Inc (SABS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, SAB Biotherapeutics Inc (SABS) has a cash flow conversion efficiency ratio of -0.112x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-24.11 Million) by net assets ($214.78 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see SAB Biotherapeutics Inc market cap and net worth for the company's overall valuation and market capitalisation.
SAB Biotherapeutics Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how SAB Biotherapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
SAB Biotherapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SAB Biotherapeutics Inc ranked by their cash flow conversion efficiency. Explore cash flow quality index of SAB Biotherapeutics Inc to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Guangdong Tianhe Agricultural Means
SHE:002999
|
-0.233x |
|
Daeduck Co. Ltd.
KO:008060
|
0.008x |
|
Zhejiang Yangfan New Materials Co Ltd
SHE:300637
|
0.053x |
|
Materialise NV
NASDAQ:MTLS
|
0.027x |
|
Banvit Bandirma Vitaminli Yem Sanayi AS
IS:BANVT
|
-0.067x |
|
Thoresen Thai Agencies Public Company Limited
BK:TTA
|
-0.003x |
|
Computer Direct
TA:CMDR
|
0.082x |
|
Ercros
MC:ECR
|
0.137x |
Annual Cash Flow Conversion Efficiency for SAB Biotherapeutics Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of SAB Biotherapeutics Inc from 2019 to 2025. View latest SAB Biotherapeutics Inc stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $151.49 Million | $-44.78 Million | -0.296x | +77.62% |
| 2024-12-31 | $25.97 Million | $-34.29 Million | -1.320x | -201.21% |
| 2023-12-31 | $57.30 Million | $-25.12 Million | -0.438x | +41.96% |
| 2022-12-31 | $31.06 Million | $-23.46 Million | -0.755x | -1565.54% |
| 2021-12-31 | $38.55 Million | $1.99 Million | 0.052x | -79.90% |
| 2020-12-31 | $39.01 Million | $10.00 Million | 0.256x | -93.58% |
| 2019-12-31 | $-2.31 Million | $-9.21 Million | 3.997x | -- |
About SAB Biotherapeutics Inc
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes … Read more